Drug-induced altered self-presentation increases tumor immunogenicity

Biomed Pharmacother. 2023 Sep:165:115241. doi: 10.1016/j.biopha.2023.115241. Epub 2023 Jul 29.

Abstract

Anti-human immunodeficiency virus (HIV) drug abacavir (ABC) binds to the specific allele of human leukocyte antigen (HLA-B*57:01) and activates CD8+ T cells by presenting altered abnormal peptides. Here, we examined the effect of ABC-induced altered self-presentation by HLA-B*57:01 on immunogenicity of cancer cells and CD8+ T-cell-dependent anti-tumor immunity. We established human-mouse chimeric HLA-B*57:01-expressing tumor cell lines (B16F10 and 3LL) and tested the anti-tumor effect of ABC in vivo. ABC treatment inhibited the growth of HLA-B*57:01-expressing tumors by a CD8+ T-cell-dependent mechanism. ABC treatment induced CXCR3-dependent infiltration of CD8+ T cells into HLA-B*57:01-expressing tumors, and activated those tumor-infiltrating CD8+ T cells to proliferate and secrete IFN-γ. The activation of CD8+ T cells using drug-induced altered self-presentation may be a new strategy to increase tumor immunogenicity and improve the efficacy of immunotherapy.

Keywords: Abacavir; Altered self-presentation; CD8(+) T cell; Cancer immunotherapy; MHC.

MeSH terms

  • Animals
  • Antigens, Neoplasm*
  • CD8-Positive T-Lymphocytes*
  • Cell Line, Tumor
  • Immunotherapy
  • Mice

Substances

  • Antigens, Neoplasm